GlassScriptPhysician profile
Shahram Khalid
NPI 1922337476
$8,567.71
in general payments reported to CMS, 2019-2025
50 companies · $1,969 in 2025
The $1,969 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $564 · 2020: $440 · 2021: $628 · 2022: $1,383 · 2023: $1,757 · 2024: $1,827 · 2025: $1,969.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,418 · Education: $135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,418.00 |
| Education | $134.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $871.33 | 2019-2025 | |
| Ucb, INC. | $749.33 | 2021-2025 | Briviact, Rystiggo, Fintepla |
| Abbvie INC. | $711.79 | 2021-2025 | |
| Mdd US Operations, LLC | $668.90 | 2019-2022 | |
| Biogen, INC. | $551.26 | 2020-2025 | Tysabri, Vumerity, Leqembi |
| Genentech USA, INC. | $443.74 | 2023-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Pfizer INC. | $385.62 | 2023-2025 | |
| Amneal Pharmaceuticals LLC | $309.35 | 2021-2024 | Rytary, Ongentys, Ongentys 50mg Capsules 30 |
| Sk Life Science, INC. | $290.81 | 2020-2024 | |
| Eisai INC. | $285.86 | 2024-2025 | |
| Lilly USA, LLC | $280.64 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Tg Therapeutics, INC. | $270.24 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $256.65 | 2020-2023 | Ajovy, Austedo, Austedo Xr |
| Argenx US, INC. | $217.46 | 2022-2024 | Vyvgart, Vyvgart Hytrulo |
| Amgen INC. | $180.13 | 2020-2025 | Uplizna |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shahram Khalid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.